WO2004096778A1 - Substituierte dihydrochinazoline mit antiviralen eigenschaften - Google Patents

Substituierte dihydrochinazoline mit antiviralen eigenschaften Download PDF

Info

Publication number
WO2004096778A1
WO2004096778A1 PCT/EP2004/004103 EP2004004103W WO2004096778A1 WO 2004096778 A1 WO2004096778 A1 WO 2004096778A1 EP 2004004103 W EP2004004103 W EP 2004004103W WO 2004096778 A1 WO2004096778 A1 WO 2004096778A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
trifluoromethyl
alkyl
phenyl
fluorine
Prior art date
Application number
PCT/EP2004/004103
Other languages
German (de)
English (en)
French (fr)
Inventor
Tobias Wunberg
Judith Baumeister
Ulrich Betz
Mario Jeske
Thomas Lampe
Susanne Nikolic
Jürgen Reefschläger
Rudolf Schohe-Loop
Frank SÜSSMEIER
Holger Zimmermann
Rolf Grosser
Kerstin Henninger
Guy Hewlett
Jörg Keldenich
Dieter Lang
Peter Nell
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004096778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HK06112993.6A priority Critical patent/HK1092463B/xx
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Priority to SI200430301T priority patent/SI1622880T1/sl
Priority to UAA200511418A priority patent/UA82519C2/uk
Priority to NZ543317A priority patent/NZ543317A/en
Priority to BRPI0410029A priority patent/BRPI0410029B8/pt
Priority to EP04728119.1A priority patent/EP1622880B3/de
Priority to DK04728119.1T priority patent/DK1622880T6/da
Priority to AU2004233978A priority patent/AU2004233978B2/en
Priority to ES04728119.1T priority patent/ES2284007T7/es
Priority to DE502004003052T priority patent/DE502004003052D1/de
Priority to MXPA05011707A priority patent/MXPA05011707A/es
Priority to JP2006505178A priority patent/JP4733631B2/ja
Priority to CA2524069A priority patent/CA2524069C/en
Priority to PL04728119T priority patent/PL1622880T6/pl
Publication of WO2004096778A1 publication Critical patent/WO2004096778A1/de
Priority to IL171513A priority patent/IL171513A/en
Priority to ZA2005/08710A priority patent/ZA200508710B/en
Priority to EGNA2005000688 priority patent/EG25273A/xx
Priority to NO20055649A priority patent/NO333265B3/no
Priority to CY20071100709T priority patent/CY1106476T1/el
Priority to NL300933C priority patent/NL300933I2/nl
Priority to HUS1800018C priority patent/HUS1800018I1/hu
Priority to CY2018019C priority patent/CY2018019I2/el
Priority to NO2018022C priority patent/NO2018022I1/no
Priority to FR18C1029C priority patent/FR18C1029I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the invention relates to substituted dihydroquinazolines and processes for their preparation and their use for the preparation of medicaments for the treatment and / or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegaloviruses.
  • An object of the present invention is therefore to provide new compounds having the same or improved antiviral activity for the treatment of viral infectious diseases in humans and animals.
  • the invention relates to compounds of the formula
  • Ar is aryl, wherein aryl may be substituted with from 1 to 3 substituents, wherein the substituents are independently selected from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxy, amino , Alkylamino, aminocarbonyl and nitro, wherein alkyl may be substituted with 1 to 3 substituents, wherein the substituents are independently selected from the group consisting of halogen, amino, alkylamino, hydroxy and aryl,
  • R 1 is hydrogen, amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro or trifluoromethyl,
  • R 2 is hydrogen, alkyl, alkoxy, alkylthio, cyano, halogen, nitro or trifluoromethyl,
  • R 3 is amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro, trifluoromethyl, alkylsulfonyl or alkylaminosulfonyl
  • R 1 , R 2 and R 3 is hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl and the other two together with the carbon atoms to which they are attached, a 1,3-dioxolane, a cyclopentane Ring or form a cyclohexane ring,
  • R 4 is hydrogen or alkyl
  • R 5 is hydrogen or alkyl
  • radicals R 4 and R 5 in the piperazine ring are bonded to exactly opposite carbon atoms and form an optionally substituted with 1 to 2 methyl groups methylene bridge,
  • R 6 is alkyl, alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxy or nitro,
  • R 7 is hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxy or nitro
  • R 8 is hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxy or nitro,
  • Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts, compounds mentioned below as examples (e) and their salts, solvates and solvates of the salts, as far as those of the formula (I) are concerned,
  • the compounds mentioned below are not already salts, solvates and solvates of the salts.
  • the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers).
  • the invention therefore relates to the enantiomers or diastereomers and their respective mixtures. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform components can be isolated in a known manner.
  • the present invention encompasses all tautomeric forms.
  • Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. However, also included are salts which are not suitable for pharmaceutical applications themselves but can be used, for example, for the isolation or purification of the compounds according to the invention.
  • Physiologically acceptable salts of the compounds of the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid acetic acid, trifluoroacetic acid, propionic acid
  • Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, by way of example and by way of illustration, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
  • solvates are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates
  • Alkoxy is, by way of example and by way of preference, methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • Alkylamino is an alkylamino radical having one or two (independently selected) alkyl substituents, by way of example and by preference methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexylamino, _Y_V-dimethylamino, N, N-diethylamino, N-ethyl-N-methylamino, N-methyl-Nn-propylamino, N-isopropyl-n-propylamino, _V " -tert-butyl-N-methylamino, N-ethyl-iV-n-pentylamino and _V-n- Hexyl-i-methylamino.
  • CC 3 -alkylamino is, for example, a monoalkylamino radical having 1 to 3 carbon atom
  • Alkylsulfonyl is, by way of example and by way of preference, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, tert-butylisulfonyl, n-pentylsulfonyl and n-hexylsulfonyl.
  • Alkylaminosulfonyl is an alkylaminosulfonyl radical having one or two (independently selected) alkyl substituents, by way of example and preferably methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, isopropylaminosulfonyl, tert-butylaminosulfonyl, n-pentylaminosulfonyl, n-hexylaminosulfonyl, N, N-dimethylaminosulfonyl, _Y_V diethyl aminosulfonyl, N-ethyl-N-methylaminosulfonyl, N-methyl-Nn-propylaminosulphonyl, TV-isopropyl-Nn-propylaminosulphonyl, N-tert-butyl-.v '-methylaminosulfonyl, N
  • C 1 -C 3 -alkylaminosulfonyl is, for example, a monoalkylaminosulfonyl radical having 1 to 3 carbon atoms or a dialkylaminosulfonyl radical having in each case 1 to 3 carbon atoms per alkyl substituent.
  • Alkylcarbonyl is exemplary and preferably acetyl and propanoyl.
  • Alkoxycarbonyl is, by way of example and by way of preference, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl.
  • Aryl is a mono- to tricyclic aromatic, carbocyclic radical having usually 6 to 14 carbon atoms; by way of example and preferably phenyl, naphthyl and phenanthrenyl.
  • Halogen is fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
  • a symbol * on a carbon atom means that the compound is in enantiomerically pure form with respect to the configuration at this carbon atom, which in the context of the present invention means an enantiomeric excess of more than 90% (> 90% ee).
  • Ar is phenyl, wherein phenyl may be substituted with 1 to 3 substituents, wherein the
  • Substituents are independently selected from the group consisting of
  • R 1 is hydrogen, C r C 3 alkyl, CC 3 alkoxy, C r is C 3 alkylthio, fluorine or chlorine,
  • R 2 is hydrogen, C r C 3 alkyl, C, -C3 alkoxy, C, -C 3 alkylthio, fluorine or chlorine,
  • R 3 is 3 alkylsulfonyl for C ⁇ -C alkyl, cyano, fluorine, chlorine, nitro, trifluoromethyl or C r C,
  • R 1 , R 2 and R 3 is hydrogen, C r C 3 alkyl, C r C 3 alkoxy, cyano, halogen, nitro or trifluoromethyl and the other two together with the carbon atoms to which they are attached , form a cyclopentane ring or a cyclohexane ring,
  • R 4 is hydrogen or methyl
  • R 5 is hydrogen
  • R 6 is CC 3 -alkyl-C r C 3 -alkoxy, carboxyl, aminocarbonyl, trifluoromethyl, fluorine, chlorine, cyano, hydroxy or nitro,
  • R 7 is hydrogen, C r C 3 alkyl, C 3 -C 3 alkoxy, fluorine, chlorine, cyano or hydroxy
  • R 8 is hydrogen, C r C 3 alkyl, C r C alkoxy, fluoro, chloro, cyano or hydroxy.
  • Ar is phenyl, wherein phenyl may be substituted with 1 to 2 substituents, wherein the substituents are independently selected from the group consisting of methyl, methoxy, fluorine and chlorine,
  • R 1 is hydrogen, methyl, methoxy, methylthio, fluorine or chlorine
  • R 2 is hydrogen
  • R 3 is methyl, iso-propyl, tert-butyl, cyano, fluorine, chlorine, nitro or trifluoromethyl,
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is aminocarbonyl, fluorine, chlorine, cyano or hydroxy
  • R 7 is hydrogen
  • R 8 is hydrogen, fluorine or chlorine.
  • Ar is phenyl, wherein phenyl may be substituted with 1 to 2 substituents, wherein the substituents are independently selected from the group consisting of methyl, methoxy, fluorine and chlorine,
  • R 1 is hydrogen, methyl, methoxy, methylthio, fluorine or chlorine
  • R 2 is hydrogen
  • R 3 is methyl, tert-butyl, cyano, fluorine, chlorine, nitro or trifluoromethyl,
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is aminocarbonyl, fluorine, chlorine, cyano or hydroxy
  • R 7 is hydrogen
  • R 8 is hydrogen, fluorine or chlorine.
  • particularly preferred compounds of the formula (I) are those in which
  • Ar is phenyl, wherein phenyl may be substituted with 1 to 2 substituents, wherein the substituents are independently selected from the group consisting of methyl, methoxy, fluorine and chlorine,
  • R 1 is hydrogen or methoxy
  • R 2 is hydrogen
  • R 3 is methyl, tert-butyl, chloro or trifluoromethyl
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is aminocarbonyl or fluorine
  • R 7 is hydrogen
  • R 8 is hydrogen or fluorine.
  • radical definitions given in detail in the respective combinations or preferred combinations of radicals are also replaced, irrespective of the particular combinations of the radicals indicated, by radical definitions of other combinations.
  • the invention further provides a process for the preparation of the compounds of the formula (I), where compounds of the formula
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 have the abovementioned meaning and
  • R 9 is alkyl, preferably methyl or ethyl or tert-butyl
  • the reaction is carried out in the case of methyl and ethyl generally with bases in inert solvents, preferably in a temperature range from room temperature to the reflux of the solvent at atmospheric pressure.
  • bases are alkali metal hydroxides such as sodium, lithium or potassium hydroxide, or alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, if appropriate in aqueous solution, sodium hydroxide in water is preferred.
  • Inert solvents are, for example, ethers, such as 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols, such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or mixtures of solvents, preferably kart is dioxane or tetrahydrofuran.
  • ethers such as 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether
  • alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or mixtures of solvents, preferably kart is dioxane or tetrahydrofuran.
  • reaction takes place in the case of tert-butyl generally with acids in inert solvents, preferably in a temperature range from 0 ° C to 40 ° C at atmospheric pressure.
  • Suitable acids in this case are hydrogen chloride in dioxane, hydrogen bromide in acetic acid or trifluoroacetic acid in methylene chloride.
  • R 6 , R 7 , R 8 and R 9 have the abovementioned meaning
  • R, R and R have the abovementioned meaning
  • the reaction takes place in both stages generally in inert solvents, preferably in a temperature range from room temperature to 100 ° C at atmospheric pressure.
  • silica gel is added to the reaction mixture.
  • the reaction is preferably carried out with a work-up between the first and the second stage.
  • Inert solvents are, for example, halogenated hydrocarbons such as methylene chloride, trichloromethane, tetrachloromethane, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichlorethylene, ethers such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents such as dimethylformamide, dimethylacetamide, acetonitrile or ethyl acetate, or mixtures of solvents, methylene chloride is preferred.
  • halogenated hydrocarbons such as methylene chloride, trichloromethan
  • the compounds of the formula (IV) are known or can be synthesized by known processes from the corresponding starting materials.
  • the compounds of the formula (V) are known or can be synthesized by known processes from the corresponding starting materials, for example by a Buchwald-Hartwig reaction according to the following synthesis scheme (reviewed in: CG Frost, P. Mendonca, J. Chem. Perkin Trans I, 1998, 2615-2623):
  • the educts required for this purpose are known or can be synthesized by known processes from the corresponding starting materials.
  • R, R, R and R have the abovementioned meaning
  • the reaction is generally carried out in inert solvents, in the presence of a base, preferably in a temperature range from room temperature to 50 ° C. under atmospheric pressure.
  • Inert solvents are, for example, ethers, such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents, such as dimethylformamide , Dimethylacetamide, acetonitrile or pyridine, acetonitrile is preferred.
  • ethers such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether
  • hydrocarbons such as benzene, xylene, toluene, hexane, cyclohe
  • bases are alkali metal and alkaline earth metal carbonates such as cesium carbonate, sodium or potassium carbonate or amines such as triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine, triethylamine being preferred.
  • the compounds of the formula (VI) are known or can be synthesized by known processes from the corresponding starting materials, for example by a Heck reaction or a Wittig-Horner reaction according to the following synthesis schemes:
  • the educts required for this purpose are known or can be synthesized by known processes from the corresponding starting materials.
  • the compounds of the general formula (I) according to the invention show an unforeseeable, surprising activity spectrum. They show an antiviral activity against representatives of the group of herpes viridae (herpesviruses), especially against cytomegaloviruses (CMV), especially against the human cytomegalovirus (HCMV).
  • herpes viridae herpes viridae
  • CMV cytomegaloviruses
  • HCMV human cytomegalovirus
  • Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, especially of infections with viruses, in particular the viruses mentioned above, and the infectious diseases caused thereby.
  • a virus infection is understood below to mean both an infection with a virus and an infection caused by a virus.
  • Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
  • the compounds according to the invention are preferably used for the preparation of medicaments which are suitable for the prophylaxis and / or treatment of infections with a member of the group of herpes viridae, in particular a cytomegalovirus, in particular the human cytomegalovirus.
  • Another object of the present invention is a method for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases, using an antiviral effective amount of the compounds of the invention.
  • compositions containing at least one compound of the invention and at least one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
  • suitable combination active ingredients may be mentioned by way of example and preferably: antiviral agents such as gancyclovir or acyclovir.
  • antiviral agents such as gancyclovir or acyclovir.
  • the compounds according to the invention can act systemically and / or locally. For this purpose, they may be applied in a suitable manner, such as, for example, orally, parenterally, pulmonarily, nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, otically or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenous, intraarterial, intracardiac, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal).
  • a resorption step e.g., intravenous, intraarterial, intracardiac, intraspinal, or intralumbar
  • absorption e.g., intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal.
  • parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • Inhalation medicines including powder inhalers, nebulizers
  • nasal drops solutions, sprays
  • lingual, sublingual or buccal tablets films / wafers or capsules
  • suppositories ear or eye preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures)
  • lipophilic suspensions ointments, creams, transdermal therapeutic systems, milk, pastes, foams , Scattering powders, implants or stents.
  • excipients for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecyl sulfate, polyoxysorbitanoleate
  • binders for example polyvinylpyrrolidone
  • synthetic tables and natural polymers for example, albumin
  • stabilizers for example, antioxidants such as ascorbic acid
  • dyes eg, inorganic pigments such as iron oxides
  • flavor and / or smell corrigents include, among others, excipients (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic tables and natural polymers (for example, albumin), stabilize
  • compositions containing at least one compound of the invention usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
  • the dosage is about 0.01 to 25 mg / kg, preferably 0.1 to 10 mg / kg of body weight.
  • Method 1 (analytical HPLC): column: Kromasil C18 60 mm x 2 mm; Temperature: 30 ° C; Flow: 0.75 ml / min; Eluent A: 0.005 M HC10 4 , eluent B: acetonitrile; Gradient: -> 0.5 min 98% A, - ⁇ 4.5 min 10% A, ⁇ 6.5 min 10% A.
  • Method 2 (preparative HPLC): column: GromSil C18, 250 mm ⁇ 30 mm; Flow: 50 ml / min; Running time: 38 min; Detection: 210 nm; Eluent A: water, eluent B: acetonitrile, gradient: 10% B (3 min) -> 90% B (31 min) -> 90% B (34 min) -> 10% B (34.01 min).
  • Method 3 (LC-MS): Column: GromSil 120 ODS-4 HE, 50 mm ⁇ 2.0 mm, 3 ⁇ m; Eluent A: 11 water + 1 ml 50% formic acid, eluent B: 11 acetonitrile + 1 ml 50% formic acid; Gradient: 0.0 min 100% A -5 »0.2 min 100% A -> 2.9 min 30% A -» 3.1 min 10% A - »4.5 min 10% A; Oven: 55 ° C; Flow: 0.8 ml / min; UV detection: 208-400 nm.
  • Method 4 (preparative HPLC, enantiomer separation, carboxylic acids): Column: packing material Chiral silica gel selector KBD 8361 (420 mm ⁇ 100 mm) based on the selector poly (N-methacryloyl-L-leucine-1-menthylamide); Temperature: 23 ° C; Eluent: methyl tert-butyl ether; Flow: 100 ml / min; Compound dissolved in methyl tert-butyl ether / ethyl acetate (9: 1).
  • Method 5 (Preparative HPLC): Column: GromSil C18, 250 mm ⁇ 30 mm; Flow: 50 ml / min; Running time: 38 min; Detection: 210 nm; Eluent A: water with 0.1% formic acid, eluent B: acetonitrile, gradient: 10% B (3 min) -> 90% B (31 min) -> 90% B (34 min) -> 10% B (34.01 min) ,
  • Method 6 (analytical HPLC): instrument: HP 1100 with DAD detection; Column: Kromasil RP-18, 60 mm x 2 mm, 3.5 ⁇ m; Eluent A: 5 ml HCIO 4 / l water, eluent B: acetonitrile; Gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 9 min 90% B; Flow: 0.75 ml / min; Temp .: 30 ° C, detection: UV 210 nm.
  • Method 7 Instrument: Micromass Platform LCZ with HPLC Agilent Series 1 100; Column: Grom-SIL120 ODS-4 HE, 50 mm x 2.0 mm, 3 ⁇ m; Eluent A: 11 water + 1 ml 50% formic acid, eluent B: 11 acetonitrile + 1 ml 50% formic acid; Gradient: 0.0 min 100% A -> 0.2 min 100% A • 2.9 min 30% A - »3.1 min 10% A - 4.5 min 10% A; Oven: 55 ° C; Flow: 0.8 ml / min; UV detection: 210 nm.
  • Method 8 Instrument: Micromass Platform LCZ, HP1100; Column: Symmetry C18, 50 mm x 2.1 mm, 3.5 ⁇ m; Eluent A: acetonitrile + 0.1% formic acid, eluent B: water + 0.1%) formic acid; Gradient: 0.0 min 10% A -> 4.0 min 90% A -> 6.0 min 90% A; Oven: 40 ° C; Flow: 0.5 ml / min; UV detection: 208-400 nm.
  • Method 9 Device Type MS: Micromass ZQ; Device type HPLC: Waters Alliance 2795; Column: Merck Chromolith SpeedROD RP-18e 50 mm x 4.6 mm; Eluent A: water + 500 ⁇ l 50% formic acid / 1; Eluent B: acetonitrile + 500 ⁇ l 50% formic acid / 1; Gradient: 0.0 min 10% B - 3.0 min 95% B - 4.0 min 95% B; Oven: 35 ° C; Flow: 0.0 min 1.0 ml / min - 3.0 min 3.0 ml / min - 4.0 min 3.0 ml / min; UV detection: 210 nm.
  • Method 10 Device Type MS: Micromass ZQ; Device type HPLC: HP 1100 Series; UV DAD; Column: Grom-Sil 120 ODS-4 HE 50 mm ⁇ 2 mm, 3.0 ⁇ m; Eluent A: water + 500 ⁇ l 50% formic acid / 1, eluent B: acetonitrile + 500 ⁇ l 50% formic acid / 1; Gradient: 0.0 min 0% > B - $ » 2.9 min 70% B -_> 3.1 min 90% B -» 4.5 min 90% B; Oven: 50 ° C; Flow: 0.8 ml / min; UV detection: 210 nm.
  • Method 11 (preparative HPLC, enantiomer separation): column: packing material Chiral silica gel selector KBD 8361 (250 mm ⁇ 20 mm) based on the selector poly (N-methacryloyl-L-leucine-1-menthylamide); Temperature: 23 ° C; Eluent: methyl tert-butyl ether + 5% ethyl acetate; Flow: 25 ml / min.
  • Method 12 (preparative HPLC, enantiomer separation): Column: packing material Chiral silica gel selector KBD 5326 (250 mm ⁇ 20 mm) based on the selector poly (N-methacryloyl-L-leucine-dicyclopropylmethylamide); Temperature: 23 ° C; Eluent: methyl tert-butyl ether + 5% > ethyl acetate; Flow: 25 ml / min.
  • Method 13 (preparative HPLC, enantiomer separation): Column: packing material Chiral silica gel selector KBD 8361 (250 mm ⁇ 20 mm) based on the selector poly (N-methacryloyl-leucine-1-menthylamide); Temperature: 23 ° C; Eluent: methyl tert-butyl ether; Flow: 25 ml / min.
  • Method 14 (preparative HPLC, enantiomer separation, ester): Column: packing material Chiral silica gel selector KBD 8361 (420 mm ⁇ 100 mm) based on the selector poly (N-methacryloyl-L-leucine-1-menthylamide); Temperature: 23 ° C; Eluent: i-hexane / ethyl acetate 85/15 v / v; Flow: 100 ml / min; Compound dissolved in i-hexane / ethyl acetate (85:15).
  • Method 15 (preparative HPLC, enantiomer separation, ester): Column: packing material Chiral silica gel selector KBD 8361 (420 mm ⁇ 100 mm) based on the selector poly (N-methacryloyl-L-leucine-1-menthylamide); Temperature: 23 ° C; Eluent: methyl tert-butyl ether; Flow: 100 ml / min; Compound dissolved in methyl tert-butyl ether.
  • Method 16 Instrument: Micromass Platform LCZ with HPLC Agilent Series 1100; Column: Grom-SIL120 ODS-4 HE, 50 mm x 2.0 mm, 3 ⁇ m; Eluent A: 1 liter of water + 1 ml of 50% formic acid, eluent B: 1 liter of acetonitrile + 1 ml of 50% formic acid; Gradient: 0.0 min 100% A -> 0.2 min 100% A - »2.9 min 30% A -> 3.1 min 10% A -> 4.5 min 10% A; Oven: 55 ° C; Flow: 0.8 ml / min; UV detection: 208-400 nm.
  • Method 17 Device Type MS: Micromass ZQ; Device type HPLC: Waters Alliance 2790; Column: Grom-Sil 120 ODS-4 HE 50 mm ⁇ 2 mm, 3.0 ⁇ m; Eluent A: water + 500 ⁇ l 50% formic acid / 1; Eluent B: acetonitrile + 500 ⁇ l 50% formic acid / 1; Gradient: 0.0 min 0% B-> 0.2 min 0% B- 2.9 min 70% B ⁇ 3.1 min 90% B- 4.5 min 90% B; Oven: 45 ° C; Flow: 0.8 ml / min; UV detection: 210 nm.
  • reaction flask is thoroughly heated under high vacuum and filled with argon during aeration.
  • the flask is charged with 1.0 equivalents of bromo aryl compound and 6.0 equivalents of piperazine in absolute toluene (0.2-0.3M bromine compound solution).
  • 0.01 equivalents of tris (dibenzylideneacetone) dipalladium and 0.03 equivalents of BINAP are added.
  • the reaction mixture is stirred under reflux for 16 h.
  • the mixture is then extracted once with water, the organic phase is extracted twice with 1N hydrochloric acid, the aqueous phase is adjusted to pH 8 with 1N sodium hydroxide solution and extracted three times with dichloromethane.
  • the combined organic phases are dried over sodium sulfate, filtered, the solvent removed in vacuo and the product dried overnight under high vacuum.
  • the NMR may still indicate a fluctuating level of non-cyclized reaction product.
  • the mixture of cyclized and non-cyclized product is taken up in dioxane, mixed with a spatula tip of silica gel and stirred under reflux for 30 min to 16 h.
  • the silica gel is filtered off and the solution used for further reactions.
  • the compound is obtained as enantiomer A, by separating the racemate from Example 30A chromatographically according to Method 15 into the enantiomers. Starting from 231 g racemate gives 120 g of the target product, which is further reacted directly.
  • the compound is obtained as enantiomer A, by separating the racemate from Example 31A chromatographically according to Method 15 into the enantiomers. Starting from 231 g of racemate, 111 g (48% of theory) of the target product are obtained.
  • the target product is obtained by reacting the enantiomerically pure ester from Example 43A according to general procedure [H]. Starting from 111 g (0.19 mol) of ester, 69 g (63% of theory) of target product are obtained.
  • the target product is obtained by reacting the enantiomerically pure ester of Example 42A according to general procedure [H]. Starting from 120 g (0.21 mol) of ester, 96 g (81% of theory) of target product are obtained.
  • Enantiomer separation (Method 13) is carried out from 500 mg (0.9 mmol) racemate (Example 20). Subsequently, the crude product is dissolved in 1 N sodium hydroxide solution, extracted with diethyl ether and the aqueous phase brought to pH 4-5 with 1 N hydrochloric acid. The product is filtered off, washed with water and dried in vacuo.
  • Example 89 80 mg (0.14 mmol) of methyl ether (Example 89) are dissolved in 2 ml of dichloromethane and treated at 0 ° C with 0.41 mmol IM boron tribromide solution in dichloromethane. The mixture is stirred at room temperature for 16 hours, a further 0.82 mmol of boron tribromide solution is added and, after 24 hours, a further 1.23 mmol is added. The mixture is stirred for 24 hours at room temperature, then the reaction mixture is poured onto ice and 5 ml of an aqueous hydrochloric acid solution IN. It is extracted with 25 ml of ethyl acetate. The organic phase is washed with a saturated aqueous sodium chloride solution, dried over sodium sulfate, concentrated and purified by preparative HPLC. 50 mg (63% of theory) of product are obtained.
  • test compounds are used as 50 millimolar (mM) solutions in dimethylsulfoxide (DMSO).
  • DMSO dimethylsulfoxide
  • Ganciclovir ®, foscarnet and cidofovir ® ® used as reference compounds.
  • 2 .mu.l each of the 50, 5 0.5 and 0.05 mM DMSO stock solutions of 98 .mu.l cell culture medium in the series 2 AH in duplicate, 1: 2 dilutions with 50 ul medium to row 1 1 of the 96-well plate performed.
  • the wells in rows 1 and 12 each contain 50 ⁇ l Medimn.
  • the wells are then fixed and stained by adding a mixture of formalin and Giemsa's dye (30 minutes), with double-distilled water. washed and dried in a drying oven at 50 ° C. Thereafter, the plates are visually evaluated with an overhead microscope (Plaque Multiplier from Technomara).
  • CC 5 o (NHDF) substance concentration in uM, no visible cytostatic effects are noted during compared to the untreated cell control on the cells;
  • EC 50 substance concentration in ⁇ M, which inhibits the CPE (cytopathic effect) by 50% compared to the untreated virus control;
  • SI (selectivity index) CC S0 (NHDF) / EC50 (HCMV).
  • mice 3-4 week old female immunodeficient mice (16-18 g), Fox Chase SCID or Fox Chase SCID-NOD or SCID-beige are purchased from commercial breeders (Taconic M + B, Jackson, USA). The animals are kept in isolators under sterile conditions (including litter and food).
  • HCMV Human cytomegalovirus
  • NHDF cells human embryonic foreskin fibroblasts
  • MOI multiplicity of infection
  • FCS fetal calf serum
  • PBS Saline
  • the sponges loaded with the infected cells are incubated with 25 ⁇ l PBS / 0.1% BSA / 1 mM DTT with 5 ng / ⁇ l basic fibroblast growth factor (bFGF).
  • the immunodeficient mice are anesthetized with Avertin or with a ketamine / xylazine / azepromazine mixture, the dorsal skin is removed with the help of a razor, the epidermis is opened 1-2 cm, relieved and the wet sponges are transplanted under the dorsal skin. The surgical wound is closed with tissue glue. 6 hours after transplantation, the mice can be treated for the first time (treatment is given once on the day of the operation).
  • substance On the following days, substance will be treated orally three times daily (7:00 am and 2:00 pm and 7:00 pm), twice daily (8 am and 6 pm) or once daily (2 pm) for a period of 8 days.
  • the daily dose is for example 3 or 10 or 30 or 60 or 100 mg / kg body weight, the application volume 10 ml / kg body weight.
  • the formulation of the substances takes place in the form of a 0.5% Tylose suspension with 2% DMSO or a 0.5% Tylose suspension. 9 days after transplantation and 16 hours after the last administration of the substance, the animals are killed without pain and the sponge removed.
  • the virus-infected cells are released from the sponge by collagenase digestion (330 U / 1.5 ml) and stored at -140 ° C in the presence of MEM, 10% fetal calf serum, 10% DMSO.
  • the evaluation is carried out after serial dilution of the virus-infected cells in decimal steps by titer determination on 24-well plates of confluent NHDF cells after vital staining with neutral red. The number of infected cells or infectious virus particles (infectious center assay) after substance treatment is determined in comparison to the placebo-treated control group.
  • test substance is incubated in different concentrations with human liver microsomes (2 mg / ml microsomal protein) in potassium phosphate buffer pH 7.4 with addition of NADPH-generating system (NADP +, glucose-6-phosphate and glucose 6-phosphate dehydrogenase) at 37 ° C.
  • NADPH-generating system NADP +, glucose-6-phosphate and glucose 6-phosphate dehydrogenase
  • 2 aliquots are taken from the incubation.
  • the first aliquot is incubated 1:50 in a new incubation solution (phosphate buffer, NADPH-generating system and 10 ⁇ M midazolam) for another 10 min at 37 ° C. Thereafter, the incubation with acetonitrile is stopped on ice, pelleted in the centrifuge at 15000g, and the supernatant analyzed by HPLC / MS for the formation of 1'-hydroxymidazolam by standard methods.
  • the second aliquot is quenched with acetonitrile on ice and analyzed by HPLC / UV / MS for remaining test substance.
  • Typical parameters of both the analytical data for irreversible inhibition (k j _ act, K; and partition ratio r). Determined and the test substance thus evaluated (cf. A. Madan, et al, ed in AD Rodrigues () "drug designation.. Drug Interaction "in” Drugs and Pharmaceutical Science “, Vol. 116, ISBN 0-8247-0283.2, Marcel Dekker Inc., New York, 2002.).
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows:
  • Example 1 100 mg of the compound of Example 1, 50 mg of lactose (monohydrate), 50 mg of corn starch (native), 10 mg of polyvinylpyrrolidone (PVP 25) (BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate.
  • the mixture of active ingredient, lactose and starch is granulated with a 5% solution (m / m) of the PVP in water.
  • This mixture is compressed with a conventional tablet press (for the tablet format see above).
  • a pressing force of 15 kN is used as a guideline for the compression.
  • a single dose of 100 mg of the compound of the invention corresponds to 10 ml of oral suspension.
  • Example 1 The compound of Example 1 is dissolved together with polyethylene glycol 400 in the water with stirring.
  • the solution is sterile-filtered (pore diameter 0.22 ⁇ m) and filled under aseptic conditions into heat-sterilized infusion bottles. These are closed with infusion stoppers and crimp caps.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/EP2004/004103 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften WO2004096778A1 (de)

Priority Applications (24)

Application Number Priority Date Filing Date Title
CA2524069A CA2524069C (en) 2003-05-02 2004-04-17 Substituted dihydroquinazolines
JP2006505178A JP4733631B2 (ja) 2003-05-02 2004-04-17 抗ウイルス性を有する置換されたジヒドロキナゾリン類
SI200430301T SI1622880T1 (sl) 2003-05-02 2004-04-17 Substituirani dihidrokinazolini z antivirusnimi lastnostmi
UAA200511418A UA82519C2 (uk) 2003-05-02 2004-04-17 Заміщені дигідрохіназоліни, які мають антивірусні властивості
NZ543317A NZ543317A (en) 2003-05-02 2004-04-17 Substituted dihydrochinazolines having antiviral properties
BRPI0410029A BRPI0410029B8 (pt) 2003-05-02 2004-04-17 composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
EP04728119.1A EP1622880B3 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften
DK04728119.1T DK1622880T6 (da) 2003-05-02 2004-04-17 Substituerede dihydroquinazoliner med antivirale egenskaber
AU2004233978A AU2004233978B2 (en) 2003-05-02 2004-04-17 Substituted dihydrochinazolines having antiviral properties
ES04728119.1T ES2284007T7 (es) 2003-05-02 2004-04-17 Dihidroquinazolinas sustituidas con propiedades antivirales
DE502004003052T DE502004003052D1 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften
HK06112993.6A HK1092463B (en) 2003-05-02 2004-04-17 Substituted dihydrochinazolines having antiviral properties
PL04728119T PL1622880T6 (pl) 2003-05-02 2004-04-17 Podstawione dihydrochinazoliny o właściwościach przeciwwirusowych
MXPA05011707A MXPA05011707A (es) 2003-05-02 2004-04-17 Dihidroquinazolinas sustituidas con propiedades antivirales.
IL171513A IL171513A (en) 2003-05-02 2005-10-20 Substituted dihydrochinazolines having antiviral peroperties, pharmaceutical compositions comprising them and their preparation
ZA2005/08710A ZA200508710B (en) 2003-05-02 2005-10-27 Substituted dihydrochinazolines having antiviral properties
EGNA2005000688 EG25273A (en) 2003-05-02 2005-10-29 Substituted dihydroquinazolines.
NO20055649A NO333265B3 (no) 2003-05-02 2005-11-30 Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.
CY20071100709T CY1106476T1 (el) 2003-05-02 2007-05-25 Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
NL300933C NL300933I2 (nl) 2003-05-02 2018-04-17 Letermovir
HUS1800018C HUS1800018I1 (hu) 2003-05-02 2018-04-21 Antivirális tulajdonságú szubsztituált dihidrokinazolinok
CY2018019C CY2018019I2 (el) 2003-05-02 2018-06-29 Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
NO2018022C NO2018022I1 (no) 2003-05-02 2018-07-04 Letermovir, eller dets salt, solvat eller solvat av dets salt
FR18C1029C FR18C1029I2 (fr) 2003-05-02 2018-07-06 Dihydroquinazolines substituees a proprietes antivirales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10319612.9 2003-05-02
DE10319612A DE10319612A1 (de) 2003-05-02 2003-05-02 Substituierte Dihydrochinazoline

Publications (1)

Publication Number Publication Date
WO2004096778A1 true WO2004096778A1 (de) 2004-11-11

Family

ID=33305099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004103 WO2004096778A1 (de) 2003-05-02 2004-04-17 Substituierte dihydrochinazoline mit antiviralen eigenschaften

Country Status (38)

Country Link
US (4) US7196086B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1622880B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4733631B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100927063B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100393706C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR044078A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE355280T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2004233978B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0410029B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2524069C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2004000930A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5700764A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1106476T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE10319612A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1622880T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP056138A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG25273A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2284007T7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR18C1029I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HN (1) HN2004000146A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUS1800018I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL171513A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA27794A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05011707A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY144616A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300933I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO333265B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ543317A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20050145A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL1622880T6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1622880E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2360912C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1622880T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI335912B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA82519C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY28294A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004096778A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200508710B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113552A1 (de) * 2004-05-07 2005-12-01 Bayer Healthcare Ag Substituierte azachinazoline mit antiviraler wirkung
WO2006133822A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur herstellung von dihydrochinazolinen
KR100927063B1 (ko) 2003-05-02 2009-11-13 아이쿠리스 게엠베하 운트 코. 카게 항바이러스 특성을 갖는 치환된 디히드로퀴나졸린
JP4783738B2 (ja) * 2003-11-11 2011-09-28 アイクリス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツトゲゼルシヤフト 置換ジヒドロキナゾリンｉｉ
DE102011101446A1 (de) 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
US8343981B2 (en) 2003-05-09 2013-01-01 Aicuris Gmbh & Co. Kg Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
WO2018028556A1 (zh) * 2016-08-08 2018-02-15 南京明德新药研发股份有限公司 抗hcmv病毒化合物
JP2021512928A (ja) * 2018-02-08 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド ３，４−ジヒドロチエノ［３，２−ｄ］ピリミジン系化合物の結晶形およびその調製方法
WO2021170874A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg A method of producing a crystalline form of sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate trihydrate
WO2021170879A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate monohydrate, its preparation and use
WO2021170882A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Potassium salt of 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic acid
WO2021170875A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and sodium ions
WO2021170878A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and pharmaceutical compositions thereof
WO2023118300A1 (en) 2021-12-21 2023-06-29 Aic246 Ag & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
ES2730958T3 (es) * 2013-06-19 2019-11-13 Aicuris Anti Infective Cures Gmbh Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración oral
US9890128B2 (en) 2013-12-12 2018-02-13 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
US10392353B2 (en) * 2015-11-24 2019-08-27 Merck Sharp & Dohme Corp. Processes for making substituted quinazoline compounds using hydrogen bonding catalysts
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
JP7417715B2 (ja) 2019-09-26 2024-01-18 ノバルティス アーゲー 抗ウイルスピラゾロピリジノン化合物
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
CA3189271A1 (en) 2020-08-17 2022-02-24 Girij Pal Singh A precipitation process for amorphous letermovir
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN114031560B (zh) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 一种来特莫韦钠盐的制备方法
WO2023185597A1 (zh) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 莱特莫韦中间体及其制备方法
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN117229223A (zh) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 一种杂环衍生物及其药物组合物、应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
AU748087B2 (en) 1998-02-17 2002-05-30 Tularik Inc. Anti-viral pyrimidine derivatives
KR20010113820A (ko) 1999-04-19 2001-12-28 시오노 요시히코 옥사디아졸 고리를 갖는 술폰아미드 유도체
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6730682B2 (en) * 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DK1325008T3 (da) * 2000-07-31 2006-02-13 Hoffmann La Roche Piperazinderivater
WO2002085869A1 (de) 2001-04-19 2002-10-31 Bayer Aktiengesellschaft Arylsulfonamide als antivirale mittel
DE10138578A1 (de) 2001-08-06 2003-02-27 Bayer Ag Heterocyclylarylsulfonamide
DE10251914A1 (de) 2002-11-08 2004-05-19 Bayer Ag Substituierte Chinazoline
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10305785A1 (de) * 2003-02-12 2004-08-26 Bayer Healthcare Ag Dihydrochinazoline
DE10320780A1 (de) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituierte Dihydrochinazoline
DE10352499A1 (de) * 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituierte Dihydrochinazoline II
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
DE102004022672A1 (de) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituierte Azachinazoline
AU2006208084B2 (en) * 2005-01-25 2012-07-26 Prolexys Pharmaceuticals, Inc. Quinoxaline Derivatives as Antitumor Agents
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
BRPI0613604A2 (pt) * 2005-07-21 2011-01-18 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos
DE102006009928A1 (de) 2006-03-03 2007-09-06 Aicuris Gmbh & Co. Kg Substituierte Arylsulfonamide
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
ES2730958T3 (es) * 2013-06-19 2019-11-13 Aicuris Anti Infective Cures Gmbh Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración oral

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201765A2 (en) * 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRIBAUDO, G. ET AL: "The anticytomegaloviral activity of raltitrexed is abrogated in quiescent mouse fibroblasts that overexpress thymidylate synthase", VIRUS RESEARCH , 73(1), 57-65 CODEN: VIREDF; ISSN: 0168-1702, 2001, XP002288380 *
MARTINEZ, ANA ET AL: "Benzothiadiazine dioxide human cytomegalovirus inhibitors: Synthesis and antiviral evaluation of main heterocycle modified derivatives", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY , 14(2), 107-114 CODEN: ACCHEH; ISSN: 0956-3202, 2003, XP009033652 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49698E1 (en) 2003-02-05 2023-10-17 Aic246 Ag & Co. Kg Substituted dihydroquinazolines
USRE46791E1 (en) 2003-05-02 2018-04-17 Aicuris Anti-Infective Cures Gmbh Substituted dihydroquinazolines
KR100927063B1 (ko) 2003-05-02 2009-11-13 아이쿠리스 게엠베하 운트 코. 카게 항바이러스 특성을 갖는 치환된 디히드로퀴나졸린
US8513255B2 (en) 2003-05-02 2013-08-20 AiCuris GmbH + Co. KG. Substituted dihydroquinazolines
US8343981B2 (en) 2003-05-09 2013-01-01 Aicuris Gmbh & Co. Kg Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents
US8314113B2 (en) 2003-11-11 2012-11-20 Aicuris Gmbh & Co. Kg Substituted dihydroquinazolines II
JP4783738B2 (ja) * 2003-11-11 2011-09-28 アイクリス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツトゲゼルシヤフト 置換ジヒドロキナゾリンｉｉ
US7662822B2 (en) 2004-05-07 2010-02-16 Bayer Schering Pharma Aktiengesellschaft Substituted azaquinazolines having an antiviral action
US8198282B2 (en) 2004-05-07 2012-06-12 Aicuris Gmbh & Co. Kg Substituted azaquinazolines having an antiviral action
WO2005113552A1 (de) * 2004-05-07 2005-12-01 Bayer Healthcare Ag Substituierte azachinazoline mit antiviraler wirkung
US8084604B2 (en) 2005-06-15 2011-12-27 Aicuris GmbH & Co., KG Process for the preparation of dihydroquinazolines
RU2419617C2 (ru) * 2005-06-15 2011-05-27 Аикурис Гмбх Унд Ко. Кг Способ получения дигидрохиназолинов
US8372972B2 (en) 2005-06-15 2013-02-12 Aicuris Gmbh & Co. Kg Process for the preparation of dihydroquinazolines
CN101863843B (zh) * 2005-06-15 2013-03-27 艾库里斯有限及两合公司 制备二氢喹唑啉的方法
JP2008543797A (ja) * 2005-06-15 2008-12-04 バイエル・ヘルスケア・アクチェンゲゼルシャフト ジヒドロキナゾリン類の製造方法
WO2006133822A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur herstellung von dihydrochinazolinen
NO340521B1 (no) * 2005-06-15 2017-05-02 Aicuris Gmbh & Co Kg Fremgangsmåte for fremstilling av dihydrokinazoliner
DE102011101446A1 (de) 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "Dense Bodies" (DB)
WO2012152644A1 (de) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Herstellung von "dense bodies" (db) aus hcmv infizierten zellen
WO2013127968A1 (de) 2012-02-29 2013-09-06 Aicuris Gmbh & Co. Kg Besylat- und tosylatsalze eines dihydrochinazolinderivates und ihre verwendung als antivirale mittel
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
WO2013127970A1 (de) 2012-02-29 2013-09-06 Aicuris Gmbh & Co. Kg Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
US20150038514A1 (en) * 2012-02-29 2015-02-05 Aicuris Gmbh & Co. Kg Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents
US9512085B2 (en) 2012-02-29 2016-12-06 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
US9637459B2 (en) 2012-02-29 2017-05-02 Aicuris Gmbh & Co Kg. Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US10287254B2 (en) 2012-02-29 2019-05-14 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative
WO2013127971A1 (de) 2012-02-29 2013-09-06 Aicuris Gmbh & Co. Kg Natrium- und calciumsalze eines dihydrochinazolinderivates und ihre verwendung als antivirale mittel
USRE49897E1 (en) 2012-02-29 2024-04-02 Aic246 Ag & Co. Kg Salts of a dihydroquinazoline derivative
WO2018028556A1 (zh) * 2016-08-08 2018-02-15 南京明德新药研发股份有限公司 抗hcmv病毒化合物
US10851112B2 (en) 2016-08-08 2020-12-01 Medshine Discovery Inc. Anti-HCMV virus compound
JP2021512928A (ja) * 2018-02-08 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド ３，４−ジヒドロチエノ［３，２−ｄ］ピリミジン系化合物の結晶形およびその調製方法
JP7076845B2 (ja) 2018-02-08 2022-05-30 フェーノ・セラピューティクス・カンパニー・リミテッド ３，４－ジヒドロチエノ［３，２－ｄ］ピリミジン系化合物の結晶形およびその調製方法
WO2021170882A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Potassium salt of 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic acid
WO2021170875A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and sodium ions
WO2021170878A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and pharmaceutical compositions thereof
WO2021170879A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate monohydrate, its preparation and use
WO2021170874A1 (en) 2020-02-27 2021-09-02 Aic246 Gmbh & Co. Kg A method of producing a crystalline form of sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate trihydrate
JP7512405B2 (ja) 2020-02-27 2024-07-08 アーイーツェー２４６ アクチェンゲゼルシャフト ウント コンパニー コマンディトゲゼルシャフト ２－［（４ｓ）－８－フルオロ－２－［４－（３－メトキシフェニル）ピペラジン－１－イル］－３－［２－メトキシ－５－（トリフルオロメチル）フェニル］－４ｈ－キナゾリン－４－イル］酢酸のカリウム塩
WO2023118300A1 (en) 2021-12-21 2023-06-29 Aic246 Ag & Co. Kg Pharmaceutical compositions comprising 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and potassium ions
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation

Also Published As

Publication number Publication date
KR20060009883A (ko) 2006-02-01
CN100393706C (zh) 2008-06-11
UY28294A1 (es) 2004-11-30
USRE49698E1 (en) 2023-10-17
BRPI0410029A (pt) 2006-04-25
CO5700764A2 (es) 2006-11-30
EP1622880A1 (de) 2006-02-08
HN2004000146A (es) 2008-06-24
JP4733631B2 (ja) 2011-07-27
US20050065160A1 (en) 2005-03-24
MXPA05011707A (es) 2006-02-13
SI1622880T1 (sl) 2007-08-31
TWI335912B (en) 2011-01-11
HUS1800018I1 (hu) 2018-05-28
US7196086B2 (en) 2007-03-27
JP2006525249A (ja) 2006-11-09
ECSP056138A (es) 2006-04-19
CN1784390A (zh) 2006-06-07
RU2360912C2 (ru) 2009-07-10
ZA200508710B (en) 2006-12-27
USRE46791E1 (en) 2018-04-17
AU2004233978B2 (en) 2010-02-11
NO333265B3 (no) 2019-06-03
PL1622880T6 (pl) 2018-08-31
ES2284007T7 (es) 2018-06-20
ATE355280T1 (de) 2006-03-15
DK1622880T6 (da) 2018-06-18
FR18C1029I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-08-17
PE20050145A1 (es) 2005-05-22
NL300933I2 (nl) 2018-04-26
CY1106476T1 (el) 2012-01-25
KR100927063B1 (ko) 2009-11-13
CA2524069C (en) 2011-11-08
CY2018019I1 (el) 2018-12-12
HUS1800028I1 (hu) 2018-07-30
PT1622880E (pt) 2007-06-04
US20070191387A1 (en) 2007-08-16
NO20055649D0 (no) 2005-11-30
US8513255B2 (en) 2013-08-20
NO2018022I1 (no) 2018-07-04
NO20055649L (no) 2006-01-31
CY2018019I2 (el) 2018-12-12
AU2004233978A1 (en) 2004-11-11
MY144616A (en) 2011-10-14
EP1622880B1 (de) 2007-02-28
DK1622880T3 (da) 2007-06-25
CL2004000930A1 (es) 2005-03-18
DE502004003052D1 (de) 2007-04-12
EG25273A (en) 2011-12-04
NO333265B1 (no) 2013-04-22
FR18C1029I2 (fr) 2020-07-17
ES2284007T3 (es) 2007-11-01
NZ543317A (en) 2008-05-30
BRPI0410029B8 (pt) 2021-06-15
BRPI0410029B1 (pt) 2019-12-31
EP1622880B3 (de) 2018-05-23
DE10319612A1 (de) 2004-11-18
PL1622880T3 (pl) 2007-08-31
MA27794A1 (fr) 2006-03-01
UA82519C2 (uk) 2008-04-25
AR044078A1 (es) 2005-08-24
CA2524069A1 (en) 2004-11-11
IL171513A (en) 2011-11-30
HK1092463A1 (zh) 2007-02-09
RU2005137276A (ru) 2006-07-27
TW200510343A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
EP1622880B3 (de) Substituierte dihydrochinazoline mit antiviralen eigenschaften
DE102012101659A1 (de) Salze eines Dihydrochinazolinderivats
DE102012101673A1 (de) Salze eines Dihydrochinazolinderivats
DE102006009928A1 (de) Substituierte Arylsulfonamide
EP1853582B1 (de) Heterocyclylamid-substituierte imidazole
EP1625129B1 (de) Heterocyclyl-substituierte dihydrochinazoline und ihre verwendung als antivirale mittel
EP1603888B1 (de) 2-(3-phenyl-2-piperazinyl-3,4-dihydrochinazolin-4-yl) essigsäuren als antivirale mittel, speziell gegen cytomegalieviren
EP1685123B1 (de) Substituierte dihydrochinazoline ii
EP1751155B1 (de) Substituierte azachinazoline mit antiviraler wirkung
EP1562913B1 (de) Substituierte chinazoline als antivirale mittel, insbesondere gegen cytomegaloviren
EP1902030B1 (de) Substituierte chinolone ii
WO2004052363A1 (de) Oxazolidinone als antivirale mittel, insbesondere gegen cytomegaloviren
HK1092463B (en) Substituted dihydrochinazolines having antiviral properties
EP1499603A1 (de) Antivirale lacton-harnstoffe
DE10222024A1 (de) Lactame

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004728119

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4403/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 171513

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006505178

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005/08710

Country of ref document: ZA

Ref document number: 200508710

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2524069

Country of ref document: CA

Ref document number: 543317

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/011707

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057020720

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 05111848

Country of ref document: CO

Ref document number: 20048119284

Country of ref document: CN

Ref document number: 12005501975

Country of ref document: PH

Ref document number: 2004233978

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004233978

Country of ref document: AU

Date of ref document: 20040417

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004233978

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005137276

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057020720

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004728119

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410029

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2004728119

Country of ref document: EP